Umedica Laboratories Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Umedica Laboratories Private Limited Pharmaceutical Export Portfolio Dataset — 11 Products, $32.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Umedica Laboratories Private Limited — Pharmaceutical Exporter Profile (2026) | 11 Products, $32.2M Trade | TransData Nexus

Umedica Laboratories Private Limited

Indian Pharmaceutical Exporter · Cardiovascular Specialist · $32.2M Total Trade · DGFT Verified

Umedica Laboratories Private Limited is an Indian pharmaceutical exporter with a total trade value of $32.2M across 11 products in 8 therapeutic categories. Based on 872 verified export shipments from Indian Customs (DGFT) records, Umedica Laboratories Private Limited is the #1 Indian exporter in 1 product including Celecoxib. Top exports include Atorvastatin ($11.8M), Calcium ($7.3M), Rosuvastatin ($6.4M).

Umedica Laboratories Private Limited — Export Portfolio & Destination Treemap

Umedica Laboratories Private Limited pharmaceutical export portfolio — 11 products across 8 therapeutic categories. Source: Indian Customs (DGFT).

Who is Umedica Laboratories Private Limited? — Company Overview & Market Position

Umedica Laboratories Private Limited, established on January 5, 1982, is a prominent Indian pharmaceutical exporter specializing in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in Vapi, Gujarat, India, with its registered office located at P. No-221,222/1, GIDC Vapi, Pardi, Gujarat, 396191.

As a privately held entity, Umedica Laboratories is classified as a non-government company limited by shares. The authorized capital stands at ₹17.50 crore, with a paid-up capital of ₹3.11 crore. The company is part of the Amoli Group of Companies, reflecting a strong foundation in the pharmaceutical industry.

Umedica Laboratories has a significant global presence, exporting to over 85 countries, including the United States, European Union, Canada, Australia, Middle East, Central and South America, Africa, Asia, and CIS countries. The company's diverse product portfolio encompasses antibiotics, anti-diabetics, anti-hyperlipidemics, anti-hypertensives, NSAIDs, analgesics, antifungals, anti-malarials, antihistamines, psychotropics, diuretics, and multivitamins.

What Does Umedica Laboratories Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Atorvastatin$11.8M

Product Portfolio — Top 11 by Export Value

Umedica Laboratories Private Limited exports 11 pharmaceutical products across 8 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Atorvastatin	Cardiovascular	$11.8M	235	1.1%	6
2	Calcium	Vitamins & Supplements	$7.3M	146	0.8%	6
3	Rosuvastatin	Cardiovascular	$6.4M	226	1.4%	15
4	Celecoxib	Analgesics & Antipyretics	$3.3M	65	2.4%	1
5	Hydrocortisone	Corticosteroids	$2.1M	132	3.2%	7
6	Nifedipine	Cardiovascular	$867.8K	28	2.9%	9
7	Ranitidine	Gastrointestinal	$282.0K	23	2.2%	10
8	Roxithromycin	Advanced Antibiotics	$93.2K	3	2.2%	7
9	Indomethacin	Analgesics & Antipyretics	$91.6K	4	1.0%	11
10	Omega	Nutritional Supplements	$65.5K	6	0.3%	14
11	Praziquantel	Antimalarial & Antiparasitic	$50.1K	4	1.7%	12

Umedica Laboratories Private Limited exports 11 pharmaceutical products across 8 therapeutic categories with a total export value of $32.2M. The company is the #1 Indian exporter in 1 product: Celecoxib. The top category is Cardiovascular (58.9% of portfolio), followed by Vitamins & Supplements (22.7%), indicating a concentrated portfolio with the top 5 products accounting for 95.5% of total export value.

Umedica Laboratories Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Umedica Laboratories operates a state-of-the-art manufacturing facility located in Vapi, Gujarat. This facility is WHO-GMP approved and holds certifications from the US FDA, EU, Health Canada, TGA, and UAE MoH. The plant is equipped with advanced machinery capable of producing a wide range of formulations, including injectables, tablets, capsules, suspensions, and dry syrups.

The manufacturing capabilities are supported by a full-fledged R&D center staffed by a team of qualified and experienced scientists dedicated to improving existing products and developing new formulations. This integration of manufacturing and R&D ensures that Umedica Laboratories maintains high-quality standards and innovation in its product offerings.

3Key Leadership

The leadership team at Umedica Laboratories is headed by Managing Director Mr. Manish Umed Doshi, who has been instrumental in steering the company since its inception. Other key executives include Ms. Vandana Manish Doshi and Mr. Rupesh Suryakant Kamdar, both serving as directors, contributing to the strategic direction and growth of the company. The company secretary is Ms. Heenal Pankaj Shah, appointed on January 30, 2025, ensuring compliance and efficient corporate governance.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Umedica Laboratories Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Umedica Laboratories has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Vapi, Gujarat, is approved by the US FDA, EU, Health Canada, TGA, and UAE MoH, demonstrating compliance with international quality standards. Additionally, Umedica Laboratories has 11 approved ANDAs and 10 different products approved in the EU and UK, reflecting its commitment to meeting stringent regulatory requirements.

The company's adherence to Good Manufacturing Practices (GMP) and other regulatory standards has facilitated its market access in these regions, enabling it to supply a diverse range of pharmaceutical products to meet global healthcare needs.

2Emerging Markets

Umedica Laboratories has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's manufacturing facility has been audited and approved by regulatory authorities in countries such as Zimbabwe, Ethiopia, Tanzania, Nigeria, Uganda, Kenya, Ghana, Ivory Coast, and Malawi. This extensive regulatory compliance facilitates access to these markets, allowing Umedica Laboratories to address the growing demand for quality pharmaceuticals in these regions.

Geographic Strategy

Umedica Laboratories Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Umedica Laboratories has achieved significant milestones in the US market, with 11 approved Abbreviated New Drug Applications (ANDAs), indicating a robust portfolio of generic drug approvals. The company's manufacturing facility in Vapi, Gujarat, is registered with the US FDA, ensuring compliance with current Good Manufacturing Practices (cGMP). This registration underscores Umedica Laboratories' commitment to maintaining high-quality standards and regulatory compliance in the US market.

The company's adherence to FDA regulations and its established product approvals position it as a reliable supplier of generic pharmaceuticals in the United States.

2WHO & EU GMP

Umedica Laboratories' manufacturing facility holds WHO-GMP certification, reflecting compliance with international quality standards. Additionally, the facility has been approved by the European Union, Health Canada, TGA, and UAE MoH, demonstrating its commitment to meeting stringent regulatory requirements. These certifications and approvals facilitate Umedica Laboratories' market access in various regions, ensuring the availability of quality pharmaceutical products to meet global healthcare needs.

CDSCO & Indian Regulatory

Umedica Laboratories Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Umedica Laboratories operates in a competitive pharmaceutical industry, with several key players in the generic drug manufacturing sector. While specific market share data for Umedica Laboratories is not publicly available, the company's extensive product portfolio and global presence position it as a significant competitor in the market. The company's adherence to international quality standards and regulatory compliance further enhance its competitive edge.

2Key Differentiators

Umedica Laboratories' key differentiators include its diverse product portfolio, encompassing antibiotics, anti-diabetics, anti-hyperlipidemics, anti-hypertensives, NSAIDs, analgesics, antifungals, anti-malarials, antihistamines, psychotropics, diuretics, and multivitamins. The company's manufacturing facility in Vapi, Gujarat, is approved by the US FDA, EU, Health Canada, TGA, and UAE MoH, reflecting compliance with international quality standards. Additionally, Umedica Laboratories has 11 approved ANDAs and 10 different products approved in the EU and UK, demonstrating its commitment to meeting stringent regulatory requirements.

3Strategic Position

Frequently Asked Questions — Umedica Laboratories Private Limited

How many pharmaceutical products does Umedica Laboratories Private Limited export from India?

Umedica Laboratories Private Limited exports 11 pharmaceutical products across 8 therapeutic categories. The top exports are Atorvastatin ($11.8M), Calcium ($7.3M), Rosuvastatin ($6.4M), Celecoxib ($3.3M), Hydrocortisone ($2.1M). Total export value is $32.2M.

What is Umedica Laboratories Private Limited's total pharmaceutical export value?

Umedica Laboratories Private Limited's total pharmaceutical export value is $32.2M, based on 872 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Umedica Laboratories Private Limited the #1 Indian exporter?

Umedica Laboratories Private Limited is the #1 Indian exporter in 1 products: Celecoxib (2.4% market share).

What therapeutic categories does Umedica Laboratories Private Limited cover?

Umedica Laboratories Private Limited exports across 8 therapeutic categories. The largest are Cardiovascular (58.9%, 3 products), Vitamins & Supplements (22.7%, 1 products), Analgesics & Antipyretics (10.4%, 2 products).

Get Full Umedica Laboratories Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.